According to PBAC chair Professor Andrew Wilson, the nature and extent of the review will be determined by the government, but his personal preference is for something more comprehensive. …
Latest Video
New Stories
-
The cost of immunoglobulin is on the rise
June 27, 2019 - - Latest News -
NZ's myeloma patients rely on hope - and everything else besides PHARMAC
June 27, 2019 - - Latest News -
Does PHARMAC serve patients or its ideological self?
June 27, 2019 - - Latest News -
NICE's Dillon: Change required to manage the coming 'revolution in medicines'
June 27, 2019 - - Latest News -
MA: More required to attract emerging therapies
June 26, 2019 - - Latest News -
Recognition for Sanofi's employee well-being program
June 26, 2019 - - Latest News -
NZ: Poor access and poor outcomes
June 26, 2019 - - Latest News